文献速递抗栓抗凝管理特殊人群用药

儿科重症监护药师抗血栓干预:多中心前瞻性研究

Pharmacist antithrombotic interventions in critically ill children: A multicenter prospective study.
PubMed 文献 · Am J Health Syst Pharm · 2026-01-01

该多中心前瞻性观察研究在美国9家儿童医院开展,由41名儿科药师在697个班次中记录接受建议的干预共12632条,其中抗血栓相关干预1130条(9%),涉及693/2264例患者(26.4%)。抗血栓干预多数发生在儿童心脏重症监护病房(74.7%),约半数与抗血栓药物启动或管理相关(53.7%),且多数涉及抗凝药物(90.4%)。

要点

  • 抗血栓干预占药师接受干预的9%,涉及26.4%的重症患儿。
  • 74.7%的抗血栓干预发生在儿童心脏重症监护病房。
  • 53.7%的抗血栓干预与药物启动或管理相关,其中90.4%涉及抗凝药。

核心结论

  • 重症患儿的抗血栓干预多数在儿童心脏重症监护病房,并涉及用于血栓栓塞治疗和预防的抗凝治疗。
  • 需要进一步研究评估儿科药师驱动的临床服务及其对重症患儿抗血栓结局的影响,尤其是心脏病患儿。

研究设计与样本

  • 多中心、前瞻性、观察性研究,在美国9家儿童医院开展。
  • 参与者为儿科重症监护病房、新生儿重症监护病房、混合重症监护病房和儿童心脏重症监护病房的儿科药师。
  • 41名儿科药师在至少20个班次中记录临床活动期间提出的建议,共完成697个班次的数据收集。
  • 干预记录于中央REDCap数据库,采用描述性统计总结数据。

主要发现

  • 2023年7月至2024年11月,共记录12632条被接受的干预,涉及2264例患者。
  • 抗血栓相关干预为1130条(9%),涉及693/2264例患者(26.4%)。
  • 多数抗血栓药物干预发生在儿童心脏重症监护病房(844/1130,74.7%)。
  • 约半数抗血栓干预与抗血栓启动/管理相关(607/1130,53.7%),其中多数涉及抗凝药物(549/607,90.4%)。

临床怎么用

  • 儿科药师在重症监护中应重点关注抗血栓药物的启动与管理,尤其是抗凝药物的使用。
  • 儿童心脏重症监护病房是抗血栓药学干预的高需求区域,可优先配置药师资源。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Pharmacists play a crucial role in managing antithrombotic therapy in critically ill adults; however, data on this topic in critically ill children are limited. Therefore, we sought to characterize the types of antithrombotic therapy interventions provided by pediatric pharmacists. SUMMARY: Via a multicenter, prospective, observational study at 9 children's hospitals in the United States, pediatric pharmacists in the pediatric intensive care unit (PICU), neonatal intensive care unit (NICU), mixed intensive care unit (ICU), and pediatric cardiac intensive care unit (PCICU) at participating centers recorded recommendations made during clinical activities during at least 20 shifts. Interventions were documented in a central REDCap database. Descriptive statistics were used to summarize the data. From July 2023 to November 2024, a total of 41 pediatric pharmacists from 9 participating institutions completed data collection on interventions during 697 shifts. A total of 12,632 accepted interventions for 2,264 patients were recorded. Among the 12,632 interventions, 1,130 (9%) were antithrombotic-related interventions, involving 693/2,264 (26.4%) patients. Most antithrombotic medication interventions occurred in the PCICU (844/1,130, 74.7%). Approximately half of the antithrombotic interventions were related to antithrombotic initiation/management (n = 607/1,130, 53.7%), with the majority involving an anticoagulant medication(s) (549/607, 90.4%). CONCLUSION: The majority of antithrombotic interventions in critically ill children were in the PCICU and involved anticoagulation for thromboembolism treatment and prevention. Further research is warranted to evaluate pediatric pharmacist-driven clinical services and the impact on antithrombotic outcomes in critically ill children, particularly those with cardiac disease.

来源:Am J Health Syst Pharm,查看原文。版权归原作者所有。

引用

  1. Kiskaddon AL, Johnson PN, Dallas L, et al. Pharmacist antithrombotic interventions in critically ill children: A multicenter prospective study. Am J Health Syst Pharm. 2026. PMID: 42148541. doi:10.1093/ajhp/zxag117

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。